CAS 1105067-93-3
:Formula:C33H33FN2O4
InChI:InChI=1S/C33H33FN2O4/c1-22(2)31-30(33(40)35-26-12-7-4-8-13-26)29(23-10-5-3-6-11-23)32(24-16-18-25(34)19-17-24)36(31)21-20-27(37)14-9-15-28(38)39/h3-13,15-19,22,27,37H,14,20-21H2,1-2H3,(H,35,40)(H,38,39)/b15-9+/t27-/m0/s1
InChI key:MBPXXTUUUBBIRF-LQYYAUOTSA-N
SMILES:CC(C)C1=C(C(=C(N1CC[C@H](C/C=C/C(=O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
Atorvastatin 3-deoxyhept-2-enoic Acid ((S,E)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-5-hydroxyhept-2-enoic acid)
CAS:Heterocyclic compounds with nitrogen hetero-atom(s) only, aromatic or modified aromatic, nesoiFormula:C33H33FN2O4Color and Shape:White Off-White SolidMolecular weight:540.24244Atorvastatin EP Impurity J (Atorvastatin 3-Deoxyhept-2E-Enoic Acid)
CAS:Formula:C33H33FN2O4Color and Shape:White To Off-White SolidMolecular weight:540.64(2E)-2,3-Dehydroxy Atorvastatin
CAS:Impurity Atorvastatin 3-Deoxy-hept-2-enoic Acid Sodium Salt (USP)
Applications (2E)-2,3-Dehydroxy Atorvastatin (Atorvastatin 3-Deoxy-hept-2-enoic Acid Sodium Salt (USP)) is an impurity in the synthesis of Atorvastatin (A791750).
References Kearney, A.S., et al.: Pharm. Res., 10, 1461 (1993); Heinonen, T.M., et al.: Clin. Ther., 18, 853 (1996);Formula:C33H33FN2O4Color and Shape:NeatMolecular weight:540.622,3-Dehydroxy Atorvastatin Sodium Salt (E/Z Mixture)
CAS:Controlled ProductStability Hygroscopic
Applications Atorvastatin (A791750) impurity.
References Kearney, A.S., et al.: Pharm. Res., 10, 1461 (1993); Heinonen, T.M., et al.: Clin. Ther., 18, 853 (1996);Formula:C33H32FN2NaO4Color and Shape:NeatMolecular weight:562.61Atorvastatin 3-deoxyhept-2-enoic acid
CAS:Atorvastatin is a potent inhibitor of the enzyme HMG-CoA reductase, which is responsible for the conversion of HMG-CoA to mevalonate. This inhibition reduces the production of cholesterol and other lipids in the liver. Metabolism studies have shown that atorvastatin undergoes extensive presystemic metabolism by cytochrome P450 enzymes, primarily CYP3A4 and CYP2C9. The drug is converted to inactive metabolites that are eliminated primarily through renal excretion. Atorvastatin has not been found to inhibit any of the following: cytochrome P450 1A1/2, 2C8/9, 2D6, 2E1, 3A4/5 or glucuronidases.Formula:C33H33FN2O4Purity:Min. 95%Color and Shape:PowderMolecular weight:540.62 g/molAtorvastatin 3-deoxyhept-2-enoic acid calcium
CAS:Please enquire for more information about Atorvastatin 3-deoxyhept-2-enoic acid calcium including the price, delivery time and more detailed product information at the technical inquiry form on this pageFormula:(C33H33FN2O4)2•CaPurity:Min. 95%Molecular weight:1,121.26 g/molAtorvastatin 3-Deoxyhept-2E-Enoic Acid
CAS:Atorvastatin 3-Deoxyhept-2E-Enoic Acid, an impurity in Atorvastatin, lowers blood lipids as an HMG-CoA reductase inhibitor.Formula:C33H33FN2O4Purity:98%Color and Shape:SolidMolecular weight:540.62
